Rheumatology and immunology research最新文献

Social media broadly refers to an internet-based platform that allows for the online publication of content that is shared across a virtual community or network. Over recent years, there has been growing utilization of social media in the medical community. The field of rheumatology is no different. Social media allows for the sharing of information among rheumatologists, which can be useful in online education, disseminating research findings, forming new networks of collaborators, and discussing the latest advances in the field. However, there are several challenges facing clinicians using social media. As such, regulatory bodies have produced advisory codes of conduct to ensure better awareness concerning the appropriate use of social media among clinicians. In addition, clinicians (even those who do not use social media) need to be mindful of the fact that many patients will use these online platforms to find information, and with this comes the risk of false information. In this review, we highlight the benefits and challenges facing rheumatologists in relation to the world of social media.

The use of social media has heralded a new era of communication and social interaction, presenting important and often untapped potential and opportunity for professional organizations to thrive. In this article, we discuss the use of social media by rheumatology societies, focusing on strategy and marketing development. We share first-hand insights and tips for using social media in a way that can help rheumatology societies and professional organizations overall to thrive.

Social media has unprecedentedly impacted the world, and this includes patients and physicians alike. This article provides a glimpse of the pros and cons of social media to both parties, and how, despite its pitfalls, rheumatologists can put its use in daily practice to help bridge the gap between, and among, rheumatologists and patients to ultimately improve patient outcomes.

Social media has become an important venue for rheumatologists, patients, organizations, and other stakeholders to discuss recent research advances in diagnosis and management of rheumatic disorders. In this article, we describe the current state of how social media may enhance dissemination, discourse, and collaboration in rheumatology research. Social media may refer to social platforms like Twitter and Instagram or digital media like podcasts and other websites that are operated for providing as free, open-access medical education (FOAM). Twitter has been one of the most active social media venues and continues to host a vibrant rheumatology community. Examples of research discussions on Twitter include organic user tweets, educational threads ("tweetorials"), live-tweeting academic conferences, and journals posting recently-accepted articles. Some research collaborations have been initiated through social media interactions. Social media may also directly contribute to research by facilitating the recruitment of study participants and the collection of survey-based data. Thus, social media is an evolving and important tool to enhance research discourse, dissemination, and collaboration in rheumatology.

This review summarizes the history, function, application, and achievement of the RheumCloud App as a novel smartphone application. This App reflects the development of the Chinese Rheumatism Data Center (CRDC), which provides not only a technical platform for the database and registry of rheumatic diseases (RDs) in China, but also a close tie between Chinese rheumatologists and patients with RDs. Throughout the past decade, CRDC has successfully built the world's largest nationwide database for RDs. A total of 2074 tertiary referral centers consisting of 8051 rheumatologists participated in the registry. RheumCloud App, which is representative of the success of CRDC, has played a central role in supporting patient cohort registration, biosample collection, and patient education. Based on the data of the Rhuem-Cloud App, three national key research projects have been funded and a series of research papers have been published.

Rheumatology societies within the Asia Pacific League of Associations for Rheumatology (APLAR) serve a diverse community under challenging circumstances. The Asia-Pacific region is home to one of the fastest-growing social media populations. A survey was carried out to assess the status of these rheumatology societies' official social media platforms. An authentic source of patient information is the need of the hour in the era of digital therapeutics. Going forwards, APLAR should guide societies to establish reliable social media platforms.

Thrombotic thrombocytopenic purpura (TTP) is a life- threatening disease that can be secondary to systemic lupus erythematosus (SLE). The fist- line treatments of TTP are steroid, immunosuppressor and plasm exchange (PE). However, some patients may have a poor response to these treatments. Bortezomib is a selective proteasome inhibitor and widely used to treat patients with multiple myeloma (MM). In recent years, bortezomib has been used to treat patients with refractory TTP. Here we report a patient with refractory TTP associated with SLE and had a successful treatment with bortezomib.

Objectives: To investigate the effect of olfactory ecto-mesenchymal stem cell-derived exosomes (OE-MSC-Exos) on T follicular helper (Tfh) cell response and their implication in treating experimental Sjögrens syndrome (ESS).

Methods: C57BL/6 mice were immunized with salivary glands (SG) proteins to induce ESS mouse model. OE-MSC-Exos were added to the Tfh cell polarization condition, and the proportion of Tfh cells was detected by FCM. The PD-L1 of OE-MSCs was silenced with small interfering RNA to extract siPD-L1-OE-MSC-Exos.

Results: We found that transfer of OE-MSC-Exos markedly attenuated disease progression and reduced Tfh cell response in mice with ESS. In culture, OE-MSC-Exos potently inhibited the differentiation of Tfh cells from naïve T cells. Moreover, OE-MSC-Exos expressed high level of the ligand for the programmed cell death protein 1 (PD-L1), knocking down PD-L1 expression in OE-MSC-Exos significantly decreased their capacity to suppress Tfh cell differentiation in vitro. Consistently, transfer of OE-MSC-Exos with PD-L1 knockdown exhibited profoundly diminished therapeutic effect in ESS mice, accompanied with sustained Tfh cell response and high levels of autoantibody production.

Conclusion: Our results suggest that OE-MSC-Exos may exert their therapeutic effect in ameliorating ESS progression via suppressing Tfh cell response in a PD-L1-dependent manner.